SCHEMBL7119276

SCHEMBL7119276

COc1cc(F)ccc1OCCCN1CCN(C2=COC(C3=CC=CCC3)=CO2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 1/20 0.38
NLRP1 Q9C000 1/20 0.38
HTR1A P08908 4/20 0.37
DRD2 P14416 4/20 0.37
HTR2A P28223 4/20 0.37
ADRA1A P35348 2/20 0.37
HTR7 P34969 1/20 0.37
KDM4E B2RXH2 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HRH3 Q9Y5N1 2/20 0.36
ABCB11 O95342 1/20 0.36
CHRM2 P08172 1/20 0.36
ADRA2A P08913 1/20 0.36
CHRM1 P11229 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
DRD1 P21728 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7124339 0.91 HTR1A (0.40) ALDH1A1HTR1ADRD2HTR2AADRA1A
SCHEMBL7119008 0.91 KDM4E (0.37) ALDH1A1HTR1ADRD2HTR2AHTR7
SCHEMBL7121423 0.89 ALDH1A1 (0.36) LMNAALDH1A1SMN1; SMN2HTR1ADRD2
SCHEMBL7123074 0.87 LMNA (0.38) LMNAALDH1A1SMN1; SMN2MAPTNLRP1
SCHEMBL7125207 0.85 KDM4E (0.47) LMNAALDH1A1SMN1; SMN2MAPTNLRP1
SCHEMBL7118092 0.82 HTR1A (0.33) HTR1ADRD2HTR2ADRD1SLC6A2
SCHEMBL7130739 0.82 MEN1 (0.33) ADRA1A
SCHEMBL7128466 0.81 L3MBTL1 (0.47) LMNAALDH1A1SMN1; SMN2MAPTHTR1A
SCHEMBL7124375 0.81 HTR1A (0.33) ALDH1A1HTR1ADRD2HTR2ADRD1
SCHEMBL7123102 0.81 HRH3 (0.35) LMNAALDH1A1SMN1; SMN2HTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-03-13 US claimed
EP-1246820-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2002-10-09 EP claimed
WO-2001049683-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2001-07-12 WO claimed
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-03-13 US disclosed
EP-1246820-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2002-10-09 EP disclosed
WO-2001049683-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use CRBN, CDR2, DRD3 LMNA 2521/4885ALDH1A1 2108/4885SMN1; SMN2 3539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.